See more : BP p.l.c. (BPAQF) Income Statement Analysis – Financial Results
Complete financial analysis of Tarsus Pharmaceuticals, Inc. (TARS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tarsus Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- HYZON Motors Inc (HYZNW) Income Statement Analysis – Financial Results
- Pure Resources Limited (PR1.AX) Income Statement Analysis – Financial Results
- RDB Rasayans Limited (RDBRL.BO) Income Statement Analysis – Financial Results
- Galp Energia, SGPS, S.A. (GALP.LS) Income Statement Analysis – Financial Results
- Phihong Technology Co., Ltd. (2457.TW) Income Statement Analysis – Financial Results
Tarsus Pharmaceuticals, Inc. (TARS)
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 17.45M | 25.82M | 57.03M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.59M | 955.00K | 2.08M | 246.00K | 74.00K | 1.00K |
| Gross Profit | 15.85M | 24.86M | 54.95M | -246.00K | -74.00K | -1.00K |
| Gross Profit Ratio | 90.87% | 96.30% | 96.36% | 0.00% | 0.00% | 0.00% |
| Research & Development | 50.31M | 42.62M | 41.71M | 18.83M | 3.16M | 901.00K |
| General & Administrative | 0.00 | 44.95M | 25.40M | 8.17M | 1.14M | 449.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 108.70M | 44.95M | 25.40M | 8.17M | 1.14M | 449.00K |
| Other Expenses | 0.00 | 86.00K | -73.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 159.01M | 87.57M | 67.11M | 27.00M | 4.30M | 1.35M |
| Cost & Expenses | 160.61M | 88.53M | 69.18M | 27.00M | 4.30M | 1.35M |
| Interest Income | 10.34M | 3.50M | 36.00K | 188.00K | 40.00K | 0.00 |
| Interest Expense | 3.35M | 2.20M | 0.00 | 188.00K | 40.00K | 0.00 |
| Depreciation & Amortization | 877.00K | 789.00K | 606.00K | 246.00K | 74.00K | 1.00K |
| EBITDA | -131.67M | -59.11M | -13.17M | -26.56M | -4.56M | -1.35M |
| EBITDA Ratio | -754.69% | -229.03% | -18.55% | 0.00% | 0.00% | 0.00% |
| Operating Income | -143.16M | -62.71M | -12.16M | -27.00M | -4.30M | -1.35M |
| Operating Income Ratio | -820.53% | -242.92% | -21.32% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 7.27M | 617.00K | -1.62M | 188.00K | -371.00K | 32.00K |
| Income Before Tax | -135.89M | -62.10M | -13.77M | -26.81M | -4.67M | -1.32M |
| Income Before Tax Ratio | -778.89% | -240.53% | -24.15% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -4.00K | 55.00K | 1.00K | 1.00K | 1.00K |
| Net Income | -135.89M | -62.09M | -13.83M | -26.81M | -4.67M | -1.32M |
| Net Income Ratio | -778.89% | -240.51% | -24.25% | 0.00% | 0.00% | 0.00% |
| EPS | -4.62 | -2.52 | -0.67 | -1.32 | -0.24 | -0.31 |
| EPS Diluted | -4.62 | -2.52 | -0.67 | -1.32 | -0.24 | -0.31 |
| Weighted Avg Shares Out | 29.38M | 24.62M | 20.55M | 20.32M | 19.51M | 4.29M |
| Weighted Avg Shares Out (Dil) | 29.38M | 24.62M | 20.55M | 20.32M | 19.51M | 4.29M |
Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites
TP-03 demonstrated statistically significant and clinically meaningful improvements across two objective measures of MGD, regardless of BID or TID dosing, and was well tolerated TP-03 demonstrated statistically significant and clinically meaningful improvements across two objective measures of MGD, regardless of...
Celebrating Seeking Alpha's New Analysts - November 2023 Edition
In November, we welcomed 24 new analysts who published their first article on Seeking Alpha. This series highlights and welcomes these newcomers to our ranks of analysts who share their unique insights and perspectives as well as some of their...
Tarsus Pharmaceuticals: 3 Clinical Catalysts In The Next 4 Months, Xdemvy Launch Underway
TARS has launched a new drug, Xdemvy, for the treatment of Demodex blepharitis, with net product sales of $1.7M in the first five weeks following launch. TARS has readouts from three clinical trials due in the next four months, with...
Tarsus Pharmaceuticals, Inc. (TARS) Q3 2023 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q3 2023 Results Conference Call November 9, 2023 4:30 PM ET Company Participants David Nakasone - Head, IR Bobak Azamian - Chairman, CEO Aziz Mottiwala - CCO Jeff Farrow - CFO, CSO Conference Call Participants...
Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements
Launched XDEMVY ® (lotilaner ophthalmic solution) 0.25%, for the treatment of Demodex blepharitis
Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
IRVINE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that...
Rare Stock Picks In September 2023 - From 32 Discerning Analysts
Welcome to another installment of our monthly Rare Buy article where we highlight September investment picks you may have missed. As you know some Seeking Alpha analysts are more discerning by nature. Others are finding compelling ideas hard to come...
Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis
IRVINE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that...
Tarsus Pharmaceuticals: Worthy Of A Small Bet
Tarsus Pharmaceuticals has received FDA approval for its lotilaner ophthalmic solution for the treatment of Demodex blepharitis. The company just launched this product known by the brand name Xdemvy and is targeting optometrists and ophthalmologists. Tarsus is also developing lotilaner...
Tarsus to Present at Upcoming Investor Conferences
IRVINE, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that...
Source: https://incomestatements.info
Category: Stock Reports